Suppr超能文献

中国单中心研究:血液透析患者感染 SARS-CoV-2 奥密克戎变异株的特征和预后因素。

Characteristics and Prognostic Factors of SARS-CoV-2 Omicron Variant Infection in Hemodialysis Patients: A Single-Center Study in China.

机构信息

Department of Nephrology and Laboratory of Kidney Disease, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.

Department of Skin, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.

出版信息

Blood Purif. 2024;53(4):288-300. doi: 10.1159/000535244. Epub 2023 Nov 16.

Abstract

INTRODUCTION

This study aimed to evaluate the characteristics and prognostic factors for coronavirus disease 2019 (COVID-19) patients on maintenance hemodialysis (HD).

METHODS

All admitted HD patients who were infected with SARS-CoV-2 from December 1, 2022, to January 31, 2023, were included. Patients with pneumonia were further classified into the mild, moderate, severe, and critical illness. Clinical symptoms, laboratory results, radiologic findings, treatment, and clinical outcomes were collected. Independent risk factors for progression to critical disease and in-hospital mortality were determined by the multivariate regression analysis. The receiver operating characteristic analysis with the area under the curve was used to evaluate the predictive performance of developing critical status and in-hospital mortality.

RESULTS

A total of 182 COVID-19 patients with HD were included, with an average age of the 61.55 years. Out of the total, 84 (46.1%) patients did not have pneumonia and 98 (53.8%) patients had pneumonia. Among patients with pneumonia, 48 (49.0%) had moderate illness, 26 (26.5%) severe illness, and 24 (24.5%) critical illness, respectively. Elder age [HR (95% CI): 1.07 (1.01-1.13), p <0.01], increased levels of lactate dehydrogenase (LDH) [1.01 (1.003-1.01), p <0.01], and C-reactive protein (CRP) [1.01 (1.00-1.01), p = 0.04] were risk factors for developing critical illness. Elder age [1.11 (1.03-1.19), p = 0.01], increased procalcitonin (PCT) [1.07 (1.02-1.12), p = 0.01], and LDH level [1.004 (1-1.01), p = 0.03] were factors associated with increased risk of in-hospital mortality.

CONCLUSION

Age, CRP, PCT, and LDH can be used to predict negative clinical outcomes for HD patients with COVID-19 pneumonia.

摘要

介绍

本研究旨在评估接受维持性血液透析(HD)的 2019 冠状病毒病(COVID-19)患者的特征和预后因素。

方法

纳入 2022 年 12 月 1 日至 2023 年 1 月 31 日期间感染 SARS-CoV-2 的所有入院 HD 患者。将肺炎患者进一步分为轻症、中度、重症和危重症。收集临床症状、实验室结果、影像学表现、治疗和临床结局。通过多变量回归分析确定向重症疾病和院内死亡进展的独立危险因素。采用曲线下面积的受试者工作特征分析评估发生重症状态和院内死亡的预测性能。

结果

共纳入 182 例 COVID-19 合并 HD 患者,平均年龄为 61.55 岁。其中 84 例(46.1%)患者无肺炎,98 例(53.8%)患者有肺炎。在肺炎患者中,分别有 48 例(49.0%)为中度疾病,26 例(26.5%)为重症疾病,24 例(24.5%)为危重症疾病。年龄较大[风险比(95%置信区间):1.07(1.01-1.13),p <0.01]、乳酸脱氢酶(LDH)水平升高[1.01(1.003-1.01),p <0.01]和 C 反应蛋白(CRP)[1.01(1.00-1.01),p = 0.04]是发展为危重症的危险因素。年龄较大[1.11(1.03-1.19),p = 0.01]、降钙素原(PCT)[1.07(1.02-1.12),p = 0.01]和 LDH 水平[1.004(1-1.01),p = 0.03]升高与 HD 合并 COVID-19 肺炎患者的住院死亡率增加相关。

结论

年龄、CRP、PCT 和 LDH 可用于预测 COVID-19 肺炎 HD 患者的不良临床结局。

相似文献

3
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
4
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
6
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦/利托那韦片用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
7
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.SARS-CoV-2 中和单克隆抗体预防 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
8
Early versus late tracheostomy in critically ill COVID-19 patients.危重症 COVID-19 患者的早期与晚期气管切开术。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD015532. doi: 10.1002/14651858.CD015532.
9
Remdesivir for the treatment of COVID-19.瑞德西韦治疗 COVID-19。
Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.

本文引用的文献

8
COVID-19: mortality rates of patients on hemodialysis and peritoneal dialysis.COVID-19:血液透析和腹膜透析患者的死亡率。
Int Urol Nephrol. 2022 Oct;54(10):2713-2718. doi: 10.1007/s11255-022-03193-6. Epub 2022 Apr 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验